Cytaright 1000mg Injection

• Acute myeloid leukemia (AML)
• Chronic myelogenous leukemia (CML)
• Meningeal leukaemia

Every medicine has some side effects that typically manage on their own as your body gets used to the medicine, but some people may experience severe side effects rarely. In that case, the patient should contact the doctor immediately.

Some common side effects of Cytaright 1000mg Injection include:

• Rash
• Skin ulcer
• Nausea
• Vomiting
• Hair loss
• Abdominal pain
• Anal ulcers
• Anemia (low number of red blood cells)
• Decreased white blood cell count
• Fever
• Infection
• Abnormal liver function
• Low blood platelets
• Mouth ulcer
• Pneumonia
• Sepsis
• Mouth sore
• Stomatitis (Inflammation of the mouth)

Contact your healthcare provider if you face any unusual or persistent side effects.

• Cytaright 1000mg is available in injection form and is advised to be taken as per the doctor's prescription.
• It can be given under the skin (subcutaneous) into a vein (intravenously) into a muscle (intramuscularly) or the spine (intrathecal) by a doctor or nurse under strict medical supervision.Taking this injection in the wrong way may give you severe side effects.
• In case of overdose, contact your healthcare provider or doctor and they will provide you with medical attention. Missing or overdosing will impact the overall health of the patients and may also have side effects. So, it is always advisable to follow the prescription of the doctor strictly.
  
  

• Cytaright 1000mg Injection is a cytotoxic drug that contains Cytarabine as an active ingredient. It works by primarily killing cancer cells by interfering with their DNA synthesis.
• It causes the DNA strands to cross-link, that stops the cells from dividing and ultimately leads to their death. Results in slowing or stopping the growth of cancer cells in your body.

• Murphy, T., & Yee, K. W. (2017). Cytarabine and daunorubicin for the treatment of acute myeloid leukemia. Expert opinion on pharmacotherapy, 18(16), 1765-1780.
• Baker, W. J., Royer Jr, G. L., & Weiss, R. B. (1991). Cytarabine and neurologic toxicity. Journal of Clinical Oncology, 9(4), 679-693.
• Löwenberg, B., Pabst, T., Vellenga, E., van Putten, W., Schouten, H. C., Graux, C. ... & Ossenkoppele, G. J. (2011). Cytarabine dose for acute myeloid leukemia. New England Journal of Medicine, 364(11), 1027-1036.
• Hamada, A., Kawaguchi, T., & Nakano, M. (2002). Clinical pharmacokinetics of cytarabine formulations. Clinical pharmacokinetics, 41(10), 705-718.
• El-Subbagh, H. I., & Al-Badr, A. A. (2009). Cytarabine. In profiles of drug substances, excipients and related methodology (Vol. 34, pp. 37-113). Academic Press.